Top View
- Antigout Agents
- Lesinurad in Combination with Febuxostat in Patients With
- Zurampic), Lesinurad/Allopurinol (Duzallo
- Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: an Evidence-Based Update
- Annrheumdis-2016-209213.Full.Pdf
- Antigout Agents
- Pharmacology and Toxicology
- Gout Guideline Supplementary Appendix 6 – Network Meta
- Zurampic), Lesinurad/Allopurinol (Duzallo
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- New Drugs Reviewed by CPG May 16, 2016
- URAT1 Inhibitor Prior Authorization and Quantity Limit Criteria Program
- Recent Advances in Understanding and Managing Gout[Version 1; Peer
- Product Information for Lesinurad
- Zurampic, INN-Lesinurad
- Cross Discipline Team Leader Review
- Generic: Sumatriptan Oral Tablets/Injection
- FDA Briefing Document
- Drug Repurposing Compound Library Plus (96-Well)
- Lesinurad (Zurampic) for Gout Phung C
- Appendix A: Perioperative Medication Management
- Refractory Gout Patients
- (12) United States Patent (10) Patent No.: US 9,023,856 B2 Roberts Et Al
- Lesinurad, a Novel, Oral Compound for Gout, Acts to Decrease Serum Uric Acid Through Inhibition of Urate Transporters in the Kidney Jeffrey N
- PATIENT FACT SHEET (Zurampic)
- Physiology of Hyperuricemia and Urate-Lowering Treatments
- Antihyperuricemics Review – March 2020 Page 2 | Proprietary Information
- Lesinurad in Combination with Allopurinol
- Drug Repurposing Compound Library (96-Well)
- Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor S
- List Item Minutes of the CHMP Meeting 17-20 July 2017
- Cphi China 2020 第二十届世界制药原料中国展
- Zurampic, INN-Lesinurad
- Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Antigout Agents
- Anti-Gout Agents
- Duzallo, INN-Allopurinol/Lesinurad
- Medication Coverage Policy
- Why Does Hyperuricemia Not Necessarily Induce Gout?
- CURRENT OPINION Editorial Introductions
- ZURAMPIC (Lesinurad) Tablets, for Oral Use Tumor Lysis Syndrome Or Lesch-Nyhan Syndrome